When was Neurotype founded?

Neurotype was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Neurotype located?

Neurotype is headquartered in Minneapolis, United States.

Who is the current CEO of Neurotype?

Scott Burwell of Neurotype. They have also founded 1 company.

How many employees does Neurotype have?

As of May 31, 2026, the latest employee count at Neurotype is 2.

Is Neurotype a funded company?

Neurotype is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 15, 2020.

When was the latest funding round of Neurotype?

Neurotype's latest funding was a $***** Grant (prize money) round on Sep 30, 2023, with participation from 1 investor.

Where does Neurotype rank among its competitors?

Neurotype ranks 5th amongst 5 active competitors, of which 3 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Neurotype, which secured $329K in Sep, 2023.

Who are the top competitors of Neurotype?

Neurotype's top competitors include Pivot, Chrono Therapeutics and e-Nicotine Technology. Among them, Neurotype secured the most recent funding round in September, 2023.

Neurotype - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of next-generation neurofeedback and tools to overcome triggers for craving. It is building brain sensors and digital therapeutics to improve treatment of craving in drug and food addictions.

Website: www.neurotype.io
Social
Email ID: *****@neurotype.io

Key Metrics

Founded Year

2019

Location

Minneapolis, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Sep 30, 2023, $*****

Investors

HHS

Ranked

5^th among 5 active competitors

Employee Count

2 as on May 31, 2026

Similar Companies

Pivot & 6 more

View Neurotype's full profile

Neurotype has raised funding over 3 rounds. Its first funding round was on Sep 15, 2020. Its latest funding round was a Grant (prize money) round on Sep 30, 2023 for $*****. 1 investor participated in its latest round. Neurotype has 1 institutional investor.

Here is the list of recent funding rounds of Neurotype:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 30, 2023	7069186	Grant (prize money)	1744646	3399122	2419054	2145146
Jul 01, 2023	4274050	Grant (prize money)	8591618	7347013	5425581	3917220
Sep 15, 2020	3394173	Grant (prize money)	7993777	5896431	4655771	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Neurotype's funding rounds and investors

The founders of Neurotype is Scott Burwell. Scott Burwell is the CEO of Neurotype.

Here are the details of Neurotype's key team members:

Scott Burwell: Founder & CEO of Neurotype.
Contact Info: 1 email address

View details of Neurotype's Founder profiles and Board Members

Neurotype's employee count trend

Neurotype has 2 employees as of May 26. Here is Neurotype's employee count trend over the years:

Uncover Neurotype's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Neurotype include Pivot, Chrono Therapeutics and e-Nicotine Technology. Here is the list of Top 10 competitors of Neurotype, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Pivot 2015, San Carlos (United States), Series B	Provider of application for smoking de-addiction	$37.5M	Johnson & Johnson Innovation – JJDC, Khosla Ventures ... & 5 others	48/100
2nd	Chrono Therapeutics 2004, Waltham (United States), Deadpooled	A transdermal nicotine replacement therapy for smoking cessation.	$82.2M	Mayo Clinic Business Accelerator, Kaiser Permanente Ventures ... & 15 others	35/100
3rd	e-Nicotine Technology 2012, Los Gatos (United States), Series A	Nicotine Delivery with e-health tools to help individuals transition from smoking.	$3.98M	Xandex Investments, Green Park & Golf Ventures ... & 2 others	33/100
4th	Velectron labs 2018, Bengaluru (India), Seed	Provider of anti-addiction device	$40.9K	Bioinnovation Centre, Global Incubation Services ... & 2 others	33/100
5th	Neurotype 2019, Minneapolis (United States), Funding Raised	Provider of next-generation neurofeedback and tools to overcome triggers for craving	-	HHS	24/100
6th	Predictwatch 2016, Poland, Unfunded	Developer of technology for predicting and reducing relapse risk in addictions	-	-	20/100
7th	ODEN Health Solutions 2020, Coquitlam (Canada), Deadpooled	Provider of drug overdose detection device for drug deaddiction	-	-	16/100
8th	Lana Exprience 2022, Oman, Deadpooled	Provider of a smart solution for people dealing with substance use disorder	-	-	15/100